LIFEVANTAGE CORP Remaining Share Repurchase Authorization
LIFEVANTAGE CORP (LFVN) had Remaining Share Repurchase Authorization of $58.50 million as of 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 · last filed 2026-08-27
- 2026-06-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $58.50M.
- 2026-03-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $59.00M.
- 2025-12-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $16.70M.
- 2025-09-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $16.70M.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount |
|---|---|
| 2026-06-30 | $58.50M 10-K · filed 2026-08-27 |
| 2026-03-31 | $59.00M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $16.70M 10-Q · filed 2026-02-04 |
| 2025-09-30 | $16.70M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $17.30M 10-K · filed 2025-09-04 |
| 2025-03-31 | $19.30M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $19.30M 10-Q · filed 2025-02-05 |
| 2024-09-30 | $19.30M 10-Q · filed 2024-10-29 |
| 2024-06-30 | $20.40M 10-K · filed 2024-08-28 |
| 2024-03-31 | $22.30M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $24.20M 10-Q · filed 2024-01-30 |
| 2023-09-30 | $26.10M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $26.90M 10-K · filed 2023-08-28 |
| 2023-03-31 | $27.70M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $27.70M 10-Q · filed 2023-02-02 |
| 2022-09-30 | $27.70M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $27.70M 10-K · filed 2022-08-23 |
| 2022-03-31 | $28.10M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $4.90M 10-Q · filed 2022-02-01 |
| 2021-09-30 | $8.00M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $11.50M 10-K · filed 2021-08-19 |
| 2021-03-31 | $15.40M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $17.40M 10-Q · filed 2021-02-02 |
| 2020-09-30 | $21.40M 10-Q · filed 2020-11-03 |
| 2020-06-30 | $3.40M 10-K · filed 2020-08-18 |
| 2020-03-31 | $3.40M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $5.40M 10-Q · filed 2020-01-28 |
| 2019-09-30 | $7.50M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $8.80M 10-K · filed 2019-08-14 |
| 2019-03-31 | $11.80M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $2.00M 10-Q · filed 2019-02-04 |
| 2018-09-30 | $3.50M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $3.50M 10-K · filed 2018-08-15 |
| 2018-03-31 | $4.50M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $4.80M 10-Q · filed 2018-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |